Company Overview and News

5
CORRECTED-MOVES-Goldman Sachs changing Asia investment banking leadership - source

9h reuters
HONG KONG, Oct 21 (Reuters) - Goldman Sachs Group Inc’s veteran banker Todd Leland will become Asia investment banking head, a person with knowledge of the matter said on Sunday, adding to leadership changes at the bank since Chief Executive Officer David Solomon took over this month.
JBK GSC TFG GSJ GS GLSSP MS GJS

5
MOVES-Goldman names new Asia investment banking head amid leadership changes - source

10h reuters
HONG KONG, Oct 21 (Reuters) - Goldman Sachs Group Inc has named veteran banker Todd Leland as Asia investment banking head, a person with knowledge of the matter said on Sunday, adding to leadership changes at the bank since Chief Executive Officer David Solomon took over this month.
JBK GSC TFG GSJ GS GLSSP MS GJS

14
Exclusive: CrowdStrike hires Goldman Sachs to lead IPO - sources

2018-10-20 channelnewsasia
(This October 19 story corrects penultimate paragraph to show that Tenable shares have gained, not declined, since the company's IPO)
JBK GSC ZS TFG TENB GOOG GSJ GS GLSSP GOOGL CBLK GJS

17
DowDuPont Cements Its Rank as Dow’s Poorest Performer

2018-10-20 247wallst
DowDuPont Inc. (NYSE: DWDP) saw its share price dive again last week, although it was not the week’s biggest loser. That honor goes to IBM, which dropped more than 8% in the week. DowDuPont’s shares slipped 3.6% last week to take the stock down by 19.3% for the year to date.
IBM JBK MTSI CATR GSC CAT TFG DWDP GSJ GS GLSSP GJS MMM

5
GS / Goldman Sachs Group, Inc. (The) PROSPECTUS SUPPLEMENT NO. 4,453 DATED OCTOBER 17, 2018 (Prospectus)

2018-10-19 sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-219206
GS

5
GS / Goldman Sachs Group, Inc. (The) PROSPECTUS SUPPLEMENT NO. 4,453 DATED OCTOBER 17, 2018 (Prospectus)

2018-10-19 sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-219206
GS

5
GS / Goldman Sachs Group, Inc. (The) PRELIMINARY PROSPECTUS SUPPLEMENT DATED OCTOBER 19, 2018 (Prospectus)

2018-10-19 sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Stateme
GS

5
GS / Goldman Sachs Group, Inc. (The) PRELIMINARY PROSPECTUS SUPPLEMENT DATED OCTOBER 19, 2018 (Prospectus)

2018-10-19 sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Stateme
GS

5
GS / Goldman Sachs Group, Inc. (The) PROSPECTUS SUPPLEMENT NO. 4,497 DATED OCTOBER 17, 2018 (Prospectus)

2018-10-19 sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-219206
GS

5
GS / Goldman Sachs Group, Inc. (The) PROSPECTUS SUPPLEMENT NO. 4,497 DATED OCTOBER 17, 2018 (Prospectus)

2018-10-19 sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-219206
GS

5
GS / Goldman Sachs Group, Inc. (The) PROSPECTUS SUPPLEMENT NO. 4,516 DATED OCTOBER 17, 2018 (Prospectus)

2018-10-19 sec.gov
Table of Contents Filed Pursuant to Rule 424(b)(2)
GS

5
GS / Goldman Sachs Group, Inc. (The) PROSPECTUS SUPPLEMENT NO. 4,516 DATED OCTOBER 17, 2018 (Prospectus)

2018-10-19 sec.gov
Table of Contents Filed Pursuant to Rule 424(b)(2)
GS

5
GS / Goldman Sachs Group, Inc. (The) PROSPECTUS SUPPLEMENT NO. 4,504 DATED OCTOBER 17, 2018 (Prospectus)

2018-10-19 sec.gov
Table of Contents Filed Pursuant to Rule 424(b)(2)
GS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to GS / Goldman Sachs Group, Inc. (The) on message board site Silicon Investor.

Tell us a joke. Discuss amongst yourselves. I wonu0027t become Tell us a joke. Discuss amongst yourselves. I wonu0027t become Tell us a joke. Discuss amongst yourselves. I wonu0027t become Sears Holdings Corp. Sears Holdings Corp. Sears Holdings Corp.
wagerr - betting belongs on the blockchain wagerr - betting belongs on the blockchain wagerr - betting belongs on the blockchain Technical analysis for shorts u0026 longs Technical analysis for shorts u0026 longs Technical analysis for shorts u0026 longs
Globalstar Telecommunications Limited GSAT Globalstar Telecommunications Limited GSAT Globalstar Telecommunications Limited GSAT Things that make you go...hmmm. Things that make you go...hmmm. Things that make you go...hmmm.
Biglari Holdings, Inc. Biglari Holdings, Inc. Biglari Holdings, Inc. Your opinion please Legalization of Street Drugs Your opinion please Legalization of Street Drugs Your opinion please Legalization of Street Drugs
VeriFone Holdings, Inc. (PAY) VeriFone Holdings, Inc. (PAY) VeriFone Holdings, Inc. (PAY) Weblogs and Twitter Weblogs and Twitter Weblogs and Twitter
CUSIP: 38141G104